Home
/
Stoke Therapeutics, Inc.
/
Financials
/
Quarterly
Stoke Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Stoke Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$10.63M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$13.82M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$158.57M
May 13, 2025
Q3
2025
Sep 30, 2024
$4.89M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$4.83M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$4.22M
May 13, 2025
Q3
2024
Sep 30, 2023
$3.31M
Nov 5, 2024
Q2
2024
Jun 30, 2023
($2.48M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
$5.15M
May 6, 2024
Q3
2023
Sep 30, 2022
$2.91M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$3.23M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$3.00M
May 4, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($38.35M)
Nov 4, 2025
Q3
2025
Jun 30, 2025
($23.48M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($23.48M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
$112.88M
Nov 4, 2025
Q2
2025
Mar 31, 2025
$112.88M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$112.88M
May 13, 2025
Q3
2025
Sep 30, 2024
($26.43M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($25.70M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($25.70M)
Nov 4, 2025
Q1
2025
Mar 31, 2024
($26.37M)
May 13, 2025
Q2
2025
Mar 31, 2024
($26.37M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($26.37M)
Nov 4, 2025
Q3
2024
Sep 30, 2023
($24.54M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($30.65M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($30.65M)
Nov 5, 2024
Q2
2024
Mar 31, 2023
($22.55M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($22.55M)
May 6, 2024
Q3
2024
Mar 31, 2023
($22.55M)
Nov 5, 2024
Q3
2023
Sep 30, 2022
($26.11M)
Nov 7, 2023
Q3
2023
Jun 30, 2022
($24.65M)
Nov 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($43.09M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($27.30M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
$111.24M
May 13, 2025
Q3
2025
Sep 30, 2024
($30.00M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($29.34M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($28.37M)
May 13, 2025
Q3
2024
Sep 30, 2023
($27.23M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($33.26M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($24.69M)
May 6, 2024
Q3
2023
Sep 30, 2022
($27.15M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($25.24M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($24.80M)
May 4, 2023
Q3
2022
Sep 30, 2021
($22.68M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($22.03M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($16.83M)
May 10, 2022
Q3
2021
Sep 30, 2020
($13.71M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($13.01M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($11.74M)
May 10, 2021
Q3
2020
Sep 30, 2019
($9.84M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($8.45M)
Aug 10, 2020